By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SomaLogic said Tuesday that it has signed a multi-year research agreement with Novartis, under which the drug firm will use SomaLogics' proteomics technology to accelerate its drug discovery and development efforts.

Larry Gold, CEO of Boulder, Colo.-based SomaLogic, said in a statement that the alliance will help Novartis "define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.